EU/3/16/1752: Orphan designation for the treatment of haemophilia A

Human monoclonal IgG1 antibody against tissue factor pathway inhibitor

Table of contents

Overview

On 14 October 2016, orphan designation (EU/3/16/1752) was granted by the European Commission to Pfizer Limited, United Kingdom, for human monoclonal IgG1 antibody against tissue factor pathway (also known as PF-06741086) for the treatment of haemophilia A.

The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in November 2018.

Key facts

Active substance
Human monoclonal IgG1 antibody against tissue factor pathway inhibitor
Intended use
Treatment of haemophilia A
Orphan designation status
Positive
EU designation number
EU/3/16/1752
Date of designation
14/10/2016
Sponsor

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Brussels-Capital Region
Belgium
E-mail: orphan_enquiries@pfizer.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating